Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Editorial

Mucormycosis – An opportunistic infection in the aged immunocompromised individual: A reason for concern in COVID-19

A R T I C L E   I N F O

Keywords
SARS-CoV-2
COVID-19
Mucormycosis
Aging people
Aged
Immunocompromised
Infection
Yeast infection

In the case of hospitalised COVID-19 patients, especially aging people and those with severe symptoms who require a ventilator, corticosteroids are given in an attempt to alleviate some of the symptoms. However, steroids are known to lower immunity and raise blood sugar levels, and they tend to increase clotting factors and fibrinogen concentrations in patients. This situation provides an opportunity for pathogens to evade the human immune system and infect the host. According to a recent study, the number of cases of mucormycosis (also known as zygomycosis, black fungus) have increased in COVID-19 patients who are either hospitalised or have recovered [1]. Mucormycosis affects the nose, eyes, and brain [2] and is a potentially fatal intrusive fungal infection that frequently affects immunodeficient individuals. People with type-2 diabetes with blood sugar levels higher than 220 mg/dL, autoimmune disorders, iatrogenic immunosuppression, or hematological cancers, and organ transplant recipients are especially vulnerable to mucormycosis [3]. Mucormycosis invades sinus tissues within 3 to 4 weeks [4], and rhinocerebral mucormycosis can manifest with unusual signs and symptoms comparable to severe sinusitis, such as nasal blockage, crustng, proptosis, facial oedema, ptosis, chemosis, ophtalmoplegia, in addition to headache, fever, and other neurological symptoms [5]. Black eschar is common in the nasal cavity or over the hard palate region and penetration of blood vessels, vasculitis with thrombosis, tissue infarction, haemorrhage, and acute neutrophilic infiltrates are histopathological characteristics [6]. Without early identification and treatment, the condition may proceed rapidly, with reported fatality rates from intra-orbital and cerebral complications of 50–80%. Even with quick diagnosis, treatment of underlying conditions, and vigorous medical and surgical interventions, therapy is frequently non-effective, resulting in spread and eventual death [7]. There are several hypotheses as to what else may contribute to mucormycosis infections. Some are unlikely, such as the use of industrial oxygen or ventilation systems, age-related immune complications and non-sterile water, whilst others believe that steam inhalation may play a role by impacting the mucosa, in addition to zinc supplementation being a fungal growth promoter [8].

A complicated interaction of variables such as type-2 diabetes with or without diabetic ketoacidosis (DKA), chronic kidney disease, prior pulmonary issues, use of immunosuppressive medications, nosocomial infection sources, and immune system modifications caused by COVID-19 itself may result in secondary infections, which are becoming more recognised due to their influence on morbidity and death. COVID-19 patients admitted to an ICU, and those requiring a ventilator, or those with prolonged hospital admission (up to 50 days) are more likely to present with fungal co-infections [9]. In addition, use of corticosteroids during COVID-19 treatment may further reduce immune responses, allowing opportunistic fungal infections. It is therefore vital to be aware that COVID-19 patients, particularly those who are critically ill, may acquire secondary fungal infections and early detection is critical [10]. Other contributing factors which increase susceptibility to secondary infections include increase interleukin (IL)-1 and IL-6 along with tumor necrosis factor-alfa, while decreased levels of CD4 and CD8 T cells and persistent lymphopenia are also contributors [11]. The conclusion is made based on the 13 cross-sectional studies conducted in the China enrolling 20 to 200 confirmed cases of COVID-19 [12]. Patients with ketoacidosis present with low cytosolic pH which aids in the growth of mucor spores and corticosteroid usage further decreases the immune response to the fungus [13]. In addition, high blood glucose levels lead to transferrin and ferritin to glycosylate, which lowers iron coupling and allows for more free iron, which ultimately causes tissue damage due to generation of large amounts of reactive oxygen species [14].

Mucormycosis is rare, accounting for 1.8 cases per 1 million per year worldwide; however, during the COVID-19 pandemic more cases have
been reported (Table 1). With the emergence of the second COVID-19 wave in India in particular, a significant rise in the number of mucormycosis cases has been reported, with over 40,854 reported cases and 3,129 deaths thus far [13,15–17]. Of these reported cases, 86% were COVID-19 positive, of whom 64.1% were comorbid diabetic whilst 32% were aged 18-45 and 68% aged above 45, accounting for 27,546 cases [17]. The cases were reported in the 28 states of India with the highest numbers of cases reported in Gujarat (5,486) and Maharashtra (6,339) [18]. In a retrospective study, it was noted that patients with uncontrolled type-2 diabetes were more prone to such opportunistic infections following prolonged ventilator use in hospital [19].

In another study analysis of 101 mucormycosis patients with COVID-19, 80% were diabetic and 78.9% were male [13]. In addition, a case report described a 33-year-old woman with mucormycosis and orbital compartment syndrome who had recovered from COVID-19 and who had a history of asthma and hypertension and upon presentation in hospital had very high blood glucose levels [20]. Similarly, in a retrospective analysis of six male COVID-19 patients in India who developed rhino-orbital mucormycosis, all were diabetic and their mean age was 60.5 ± 12 [19]. A middle-aged diabetic women with non-diabetic ketoacidosis having left eye complete ptosis and facial pain with no signs of rhinitis or sinusitis was also positive for mucormycosis [21]. In a post-mortem prospective study, 10 patients with a confirmed diagnosis of SARS-CoV-2 showed a number of clinical manifestations, including thrombosis, acute tubular injury, lung damage, CD8+ T cell depletion, as well as unexpected findings, including inflammation around the heart, pancreas, and brain, and one of the 10 had disseminated mucormycosis [22]. The median age of this cohort was 73 years. These findings demonstrate the importance of early diagnosis of clinical damage due to COVID-19. Furthermore, a report of 10 cases of mucormycosis in India noted five cases of DKA, with three of them developing DKA during their hospital stay [16]. A case report in Iran described a 44-year-old diabetic woman with a 5-day history of fever, facial swelling, malaise, toothache, dry cough and partial dyspnoea who was diagnosed with mucormycosis and treated with liposomal amphotericin B [23]. Currently, there is one active clinical trial [NCT04368221], at Rennes University Hospital in France, evaluating the pervasiveness of fungal co-infections in patients with COVID-19 who are immunocompromised and on oxygen for ventilation in ICU.

Once diagnosis of mucormycosis is confirmed, surgical intervention in the affected area is required to enhance survival, but it is not a cure (Fig. 1) [31]. To begin, amphotericin-B deoxycholate, an anti-fungal treatment, is favoured due to lower toxic effects to the kidneys [32]; patients with infections tolerant to amphotericin are usually prescribed posaconazole. Even with rigorous surgery and intravenous anti-fungal treatments, the prognosis remains dismal, with documented fatality rates of 33–80%, rising to 100% in disseminated infections [5].

The cause of the outburst of mucormycosis remains a mystery. It is imperative for health professionals to be on the lookout for mucormycosis in COVID-19 patients, particularly those with type-2 diabetes, aging people, and those with facial or orbital pain or black or blood-stained sinus drainage [33]. India has contributed to almost 70% of the global cases of mucormycosis since the emergence of COVID-19 [34]. The rise in mucormycosis in India reflects the triumvirate of type-2 diabetes, widespread corticosteroid use, and SARS-CoV-2 infection; the rate increases considerably in those above 45 years of age. More recently, in India new threats have surfaced, including white and yellow fungus, bacterial infections, and a number of opportunistic respiratory

---

**Table 1.** Global picture of mucormycosis as a post-COVID-19 complication.

| Country | Number of confirmed cases | Number of confirmed deaths | References |
|---------|---------------------------|---------------------------|------------|
| USA     | 36                        | 9                         | [24,25]    |
| UK      | 7,250                     | 58                        | [26]       |
| India   | 40,854                    | 3,129                     | [13,15–17] |
| France  | 79                        | -                         | [21,27]    |
| Brazil  | 36                        | -                         | [28]       |
| Bangladesh | 2                     | 1                         | [29]       |
| Nepal   | 11                        | 2                         | [30]       |

---

**Fig. 1.** Mucormycosis – an opportunistic infection in the immunocompromised individual.
co-infections in patients with severe COVID-19 admitted to ICU [35]. All steps should be taken cautiously in order to maintain optimal blood glucose levels, and with sensible assessment-based corticosteroid usage. 

Contributors

Both authors contributed to the conceptualization, design, writing, and editing of the article and the final approval of this editorial.

Conflict of interest

The authors declare that they have no conflicts of interest.

Funding

No funding was received for the preparation of this editorial.

Provenance and peer review

This editorial was commissioned and was not externally peer reviewed.

Acknowledgments

V.A. and her team are supported by philanthropic funds from Greek Orthodox Archdiocese of Australia, The Pappas Family, and, donors to VU vaccine appeal. V.A would also like to thank the Immunology and Translational Research Group, Institute for Health and Sport, Victoria University for helpful discussions. V.P.C is grateful to the L.M. College of Pharmacy, Ahmadabad, India, for providing necessary support in carrying out the literature search. The figure in the manuscript was created using Biorender.com.

References

[1] N. Colovic, V. Arsic-Arsenijevic, A. Barac, N. Savajdzic, D. Lekovic, D. Tomin, Mucormycosis of the paranasal sinuses in a patient with acute myeloid leukemia, Exp. Arch. Colok. Lek. 144 (2016) 657–660.
[2] S. Sharma, M. Grover, S. Bhargava, S. Samdani, T. Kataria, Post coronavirus disease 25, https://doi.org/10.1186/s13054-021-03460-5.
[3] R.D. deShazo, Fungal sinusitis, Am. J. Med. Sci. 316 (1998) 39–45. https://doi.org/10.1097/00000441-199804000-00009.
[4] K. Scheckenbach, O. Cornely, T.K. Hoffmann, R. Engers, H. Bier, A. Chaker, J. Lux, S. Sharma-Hajela, B. Ravenhill, I. Hamed, L. Heales, K. Ahmadikia, S.J. Hashemi, M. Drogari-Apiranthitou, Epidemiology and diagnosis of mucormycosis in a susceptible patient: a novel phenomenon in the developing world? BMJ Case Rep. 14 (2021), e241663 https://doi.org/10.1136/bcr-2021-241663.
[5] B. Hanley, K.N. Naresh, C. Domingue, R. Guerra Del Castillo, M. Sanchez-Gonzalez, High mortality co-infections among COVID-19 patients in intensive care unit, Minerals 2021 https://timesofindia.indiatimes.com/world/south-asia/2-dead-and-11-suffering-from-black-fungus-in-nepal/articleshow/83334621.cms#:~:text=.
[6] R.D. deShazo, K. Chapin, R.E. Swain, Fungal sinusitis, N. Engl. J. Med. 337 (1997) 10.1056/NEJM199707243370407.
[7] D. González Ballester, R. González-García, C. Moreno García, L. Ruiz-Laza, F. Monje Gil, Mucormycosis of the head and neck: report of five cases with different presentations, J. Cranio-Maxillo-Facial Surg. Off. Publ. Eur. Assoc. Cranio-Maxillo-Facial Surg. 40 (2012) 584–591. https://doi.org/10.1016/j.jcms.2011.10.015.
[8] K. Schechenbach, O. Cornely, T.K. Hoffmann, R. Engers, H. Bier, A. Chaker, J. Lux, J. Schipper, M. Wagemann, Emerging therapeutic options in fulminant invasive rhinoocular mucormycosis, Auris. Nasus. Larynx. 37 (2010) 235. https://doi.org/10.1016/j.ansel.2009.09.001.
[9] S. Mehta, A. Pandey, Rhino-orbital mucormycosis associated with COVID-19, Crevs. 12 (2020) e10726, https://doi.org/10.1079/craven.19726.
[10] M. Sen, T.P. Lahane, S. Lahane, S. Fux, S. Roselius, A. Abdolrasouli, O. Cornely, M. Hovius, L. Schaefer, W. Schöder, H. Löffler, S. Rezaie, The double-edged sword of systemic corticosteroid therapy in viral pneumonia: a case report and comparative review of influence-associated mucormycosis versus COVID-19 associated mucormycosis, Mycoses (2021). https://doi.org/10.1111/myc.13256.
[11] A. Skiada, I. Pavleas, M. Drogari-Apiranthitou, Epidemiology and diagnosis of mucormycosis: an update. J. Fungi (Basel, Switzerland) 6 (2020) 265. https://doi.org/10.3390/jf6040265.
[12] L. Szapak, F. Chirico, M. Plnc, L. Szapak, T. Dzieciatkowski, Z. Rafique, Mucormycosis - a serious threat in the COVID-19 pandemic? J. Infect. https://doi.org/10.1016/j.jinf.2021.05.015. S1666-5247(21)00057-4.
[13] H. Prakash, A. Chakrabarti, Global epidemiology of mucormycosis, J. Fungi (Basel, Switzerland) 5 (2019) 25. https://doi.org/10.3390/jf5010026.
[14] B. Spellberg, T.J. Walsh, D.P. Kontoyiannis, J.J. Edwards, A.S. Ibrahim, Recent highlights: UK Records 2, 829 New Covid-19 Cases, 9 More Deaths, Hindustan Times. (2021) https://timesofindia.indiatimes.com/world/south-asia/2-dead-and-11-suffering-from-black-fungus-in-nepal/articleshow/83334621.cms#:~:text=.
[15] A. Hanif, M. Musharrat, N. Zia, P. Mehmood, S. Agha, M. Ilyas, S. Rehman, The double-edged sword of systemic corticosteroid therapy in viral pneumonia: a case report and comparative review of influenza-associated mucormycosis versus COVID-19 associated mucormycosis, Mycoses (2021). https://doi.org/10.1111/myc.13256.
[16] M. Sen, T.P. Lahane, S. Samdani, T. Kataria, Post coronavirus disease 25, https://doi.org/10.1186/s13054-021-03460-5.
[17] C.-C. Lai, C.Y. Wang, P.-R. Hsieh, Co-infections among patients with COVID-19: the need for combination therapy with non-anti-SARS-CoV-2 agents? J. Microbiol. Infect. Dis. 50 (2020) 505–512. https://doi.org/10.1016/j.jmii.2020.02.015.
[18] A.K. Singh, R. Singh, S.R. Joshi, A. Misra, Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India, Diabetes Metab. Syndr. Clin. Res. Rev. (2021), https://doi.org/10.1016/j.dsx.2021.05.019.
[19] C. Baldo, A.S. Ibrahim, Molecular mechanisms of mucormycosis - the bitter and the sweet, PLoS Pathog. 13 (2017), e1006408. https://doi.org/10.1371/journal.ppat.1006408.
[20] A. Fromm, M. Weiss, B. Hanley, K.N. Naresh, C. Domingue, R. Guerra Del Castillo, M. Sanchez-Gonzalez, High mortality co-infections of COVID-19 patients: mucormycosis and other fungal infections, Discov 9 (2021) e126. https://doi.org/10.15190/d.2021.5. Craiova, Rom.
[21] A. Hanif, M. Musharrat, N. Zia, P. Mehmood, S. Agha, M. Ilyas, S. Rehman, The double-edged sword of systemic corticosteroid therapy in viral pneumonia: a case report and comparative review of influenza-associated mucormycosis versus COVID-19 associated mucormycosis, Mycoses (2021). https://doi.org/10.1111/myc.13256.
Vivek P. Chavda\textsuperscript{a}, Vasso Apostolopoulos\textsuperscript{b,*}

\textsuperscript{a} Department of Pharmaceutics and Pharmaceutical Technology, L. M. College of Pharmacy, Ahmedabad, 380008, Gujarat, India
\textsuperscript{b} Institute for Health and Sport, Victoria University, Melbourne, VIC 3030, Australia

* Corresponding author.

E-mail addresses: vivek.chavda@lmcp.ac.in (V.P. Chavda), vasso.apostolopoulos@vu.edu.au (V. Apostolopoulos).